Friday, 21 September 2018

U.S. Personalized Medicine Market- Global Industry Size, Share, Trends, Analysis and Forecast 2018 – 2023


Market Synopsis of U.S. Personalized Medicine Market:
Market Scenario:
The Personalized Medicine Market is the most recent trend in the multibillion–dollar molecular diagnostics industry. Pharmaceutical and biotechnology companies are increasingly turning to personalized medicine in order to improve the drug development process and also to speed up the approval or sanction of new drugs.
According to the industry consensus, personalized medicine will not only form an integral part of typical medicine in the next few years, it is also anticipated to reform the development, testing, marketing and prescription of drugs during the next decade. The big pharmaceutical companies eventually will change their tried and tested epic business model to more–targeted and effective healthcare solutions. U.S personalized medicine market is expected to grow at the CAGR of 7.5% during the forecasted period.
Key players of U.S. Personalized Medicine Market:
Key players profiled in the report are Laboratory Corporation of America, Quest Diagnostics, Abbott, Becton Dickinson & Co., Siemens Healthcare Diagnostics Inc., GE Healthcare, Pfizer Inc., Sanofi, CardioDx Inc., Asuragen Inc. and Bristol-Myers Squibb.
Get Sample Copy @
https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937
Segments:
The U.S. Personalized Medicine Market is segmented on the basis of product, application and end users. Based on the product, the market has been segmented as diagnostic, therapeutics, medical care and nutrition and wellness and others. Based on application, the market has been segmented into diagnosis and intervention, drug development and usage, cancer genomics and others. Further on the basis of end users the market has been segmented as hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio and health informatics companies and others.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/2937
Detailed Table of Contents:
Table Of Contents
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
5 U.S. Personalised Medicine Market, By Product
5.1 Diagnostic
5.2 Therapeutics
5.3 Medical Care
5.4 Nutrition And Wellness
5.5 Others

...Continued

Regional analysis
U.S. accounts for the maximum market share of the personalized medicine market and the market is expected to increase continuously in coming years. This can be attributed to increasing pool of cancer patients along with high healthcare per capita expenditure. Advancing technologies within the liquid biopsy or cancer market is also driving the market and will see strategic growth over the next five years. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies which are expected to command the maximum market share.
Send An Enquiry @  https://www.marketresearchfuture.com/enquiry/2937
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Antidiuretic Drugs Market-Outlook, Regulatory Bodies, Trends, Industry Insights & Forecast

Antidiuretic substance helps to control the fluid balance in the body. Their action is opposite to that of diuretics which disrupt this balance. Major antidiuretic drugs are vasopressin (also known as antidiuretic hormone (ADH)), desmopressin, and oxytocin. In diabetes insipidus, antidiuretic drugs reduce the urine volume. Desmopressin is widely used antidiuretic drug as it is relatively inexpensive and safe having minimum adverse reactions to the body. It is primarily used for treating patients with hemophilia.  
Rising prevalence of diabetes and other chronic disease such as cardiovascular diseases, growing use of antidiuretic drugs for the treatment of hemophilia and huge patient pool with hypertension, drives the growth of antidiuretic drugs markets.
The global antidiuretic drugs market is expected to grow at a CAGR of 9.7% during the forecast period and is estimated to reach USD 180 million by 2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4306
Key Players in the Global Antidiuretic drugs Market    
Some of the key players in this market are Par Sterile Products, LLC (U.S.), ADH Health (U.S.), Azevan Pharmaceuticals, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Otsuka Holdings Co. Ltd (Japan), Taj Pharmaceuticals Limited (India) and ALLERGAN (U.S.).
Segments         
The global antidiuretic drugs market is segmented on the basis of types, which includes vasopressin, desmopressin, oxytocin, and others. Other types of antidiuretic drugs are argipressin, lypressin, ornipressin and terlipressin. On the basis of indication, the market is segmented into diabetes insipidus, hemophilia, hypertension, and others. Diabetes insipidus is further sub-segmented into central diabetes insipidus, nephrogenic diabetes insipidus, dipsogenic diabetes insipidus and gestational diabetes insipidus. Other indications are polyuria, polydipsia and enuresis. On the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies, and others.
Regional Analysis of the Global Antidiuretic drugs Market  
The American region accounted for the largest share of the global market due to increasing prevalence of diabetes insipidus, and rising demand for new drugs for the treatment of diabetes insipidus. The rate of diabetes insipidus is much higher in America than the rest of the world. According to the Diabetes Insipidus Organization, in the U.S., 1 in 6,666 American may develop diabetes insipidus. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population was suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040.
Europe is the second largest market that holds a noticeable share of the global antidiuretic drugs market. Diabetes insipidus is a common postoperative complication among children who have undergone transsphenoidal craniotomy.
In Asia Pacific, rising awareness about diabetes insipidus, huge geriatric population suffering from diabetes insipidus and increase in the risk of developing diabetes insipidus after surgery is driving the market growth. Furthermore, rising awareness about the use of antidiuretic drugs for the treatment of diabetes insipidus also propels the market growth.
Middle East and Africa show steady growth in the antidiuretic drugs market.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4306
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4306
       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Desmoid Tumors Market Challenges, Growth and Geographical Segmentation by 2023

Desmoid Tumors Market Top Key Players
Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others. 
Market Scenario
Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to the U.S National Library of Medicine, Desmoid tumors are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000 people worldwide. It is also stated that nearly 900 to 1,500 new cases are registered per year in the United States. Tumors associated with familial adenomatous polyposis (FAP) are less common than sporadic desmoid tumors.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4859

On molecular level, desmoid tumor is characterized by one of the two mutations in the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is detected, especially, when pathological differential diagnosis is difficult.
According to the Desmoid Rare Foundation, individuals within the age group of 15 and 60 are more likely to get affected by this condition. It is also stated that the condition is more prevalent in women than in men (2:1).
For the diagnosis of desmoid tumor there are many non-invasive methods available to detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The actual diagnosis of this tumor can be made only after examining a small piece of the tumor by a trained pathologist.
The symptoms of desmoid tumors include a painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by compressed nerves or muscles, and others.
The most commonly used treatment options for desmoid tumors are anti-inflammatory medication, Chemotherapy, Hormone therapy, and surgery among others. Various new therapies are under investigation such as Angiogenesis inhibitors, and Chemotherapy agents. As mutations in the CTNNB1 gene is found to be most commonly occurring in desmoid tumor. So, it is expected that very soon mutation analysis be used to predict the risk of recurrence and to aid in designing individual therapies.
Notably, the market is expected to expand in the near future due to rising demand of effective chemotherapeutic agents, high unmet needs of current treatment, and increase in research and development expenditure.
Despite these drivers, there are some issues associated with desmoid tumors market. High cost of treatment & management of desmoid tumors and related disorders, and lack of infrastructure in the middle and low income countries may hamper the growth of the market.
It is estimated that desmoid tumors market is expected to grow at a CAGR 4.5% during the forecast period of 2017-2023.
Segmentation
The desmoid tumors market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, others
On the basis of treatment, market is classified into surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, others. Novel molecular-targeted therapy is further segmented into gleevec based therapy, and sorafenib based therapy
On the basis of end-user, market is segmented into hospital, clinics, and others. 
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4859

Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Top 5 Reasons to Get this Report:
Company profiling with detailed strategies, financials, and recent development activities
Market Strategic Business Influence Data
Market Research Future recommendations in key business segments based on the market estimations
Market share analysis of the top industry players
Market forecasts for a minimum of 5 years of all the mentioned segments, Trends and the regional markets With SWOT Analysis
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4859
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Huge Growth and Opportunities in Global Cowden Syndrome Market Till 2023


Cowden syndrome is part of the PTEN hamartoma tumor syndrome. Cowden syndrome is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin. The global Cowden syndrome market is expecting a healthy growth in the coming future. The global market is majorly driven by increasing Cowden syndrome patients across the globe. Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market. However, long time for approval and side effects of the treatment may hinder the growth of the market.
The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5096

Segmentation
The global Cowden syndrome market is segmented on the basis of site, treatment and end users.
On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.
On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.
Regional Analysis
The Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.
Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.
On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.
Key Players in Global Cowden Syndrome Market
Some of key the players in the market are Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/5096  

Detailed Table of Contents for Cowden Syndrome Market
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/5096   

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Cerebral Palsy Market 2018 World Analysis and Forecast to 2023

The global cerebral palsy market is expected to grow significantly over the forecast period. Cerebral palsy (CP) refers to a group of neurological conditions that affect muscle movement and coordination. CP can be caused by damage that occurs to the immature developing brain of an infant. In addition to this, other possible causes of CP include asphyxia neonatorum, bleeding into the brain, brain infections, and severe jaundice in the infants. Cerebral palsy is the most common form of childhood disability. According to the Cerebral Palsy Guidance, around 10,000 babies are born each year in the US with cerebral palsy.
The increasing prevalence of cerebral palsy coupled with increasing awareness about the condition is anticipated to drive the global cerebral palsy market. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the overall birth prevalence of cerebral palsy is approximately 2 per 1,000 births worldwide. Moreover, the rising adoptions of medications for controlling the symptoms of the cerebral palsy are expected to boost the market growth. In addition, rising healthcare expenditure in developed economies and increasing insurance coverage contributes to the growth of the market during the assessment period. On the other hand, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hinder the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cerebral palsy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cerebral palsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cerebral palsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebral palsy market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd. are some of the key players in the global cerebral palsy market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global cerebral palsy market owing to a well-developed healthcare sector, rising prevalence of cerebral palsy and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region and a relatively large number of research and development (R&D) activities contributes to the growth of the market.
Europe is expected to hold the second largest position in the global cerebral palsy market. The market growth in this region is attributed to the growing prevalence of cerebral palsy, availability of funds for research, and increasing healthcare expenditure. According to the data stated by the National Institute for Health and Care Excellence (NICE) in 2017, in the UK, it is estimated that 1 in 400 babies are born with cerebral palsy. It also stated that approximately 1,800 children diagnosed with CP each year.
The cerebral palsy market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of cerebral palsy and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/6334   
Detailed Table of Contents:
  1. Report Prologue
  2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
  1. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
  1. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
  1. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...Continued

  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Comments (Atom)